ストックスクリーナーアプリを入手
11.75
1.47%
0.1663
Generate Biomedicines Inc (GENB) 最新ニュース
GENB PE Ratio & Valuation, Is GENB Overvalued - Intellectia AI
GENB | Generate Biomedicines, Inc. Common Institutional Ownership - Quiver Quantitative
GENB | Generate Biomedicines, Inc. Common Insider Trading - Quiver Quantitative
Insider Buying: Jane Mendillo Acquires Shares in Generate Biomed - GuruFocus
GENB: Static price chart | Generate Biomedicines, Inc. | US3709201004 - marketscreener.com
Assessing Generate Biomedicines (GENB) Valuation After Recent Share Price Volatility - simplywall.st
Generate Biomedicines Inc. (GENB) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Generate Biomedicines amends charter and bylaws ahead of Nasdaq IPO By Investing.com - Investing.com UK
Generate Biomedicines amends charter and bylaws ahead of Nasdaq IPO - Investing.com
Generate Biomedicines, Inc.Common Stock (Nasdaq:GENB) Stock Quote - FinancialContent
Generate IPO raises $400 million but shares sink - The Pharma Letter
Generate Biomedicines, Inc.(NasdaqGS: GENB) added to NASDAQ Composite Index - marketscreener.com
EBITDA of GENERATE BIOMEDICINES INC – NASDAQ:GENB - TradingView
Generate Biomedicines shares fall in weak Nasdaq debut for drug developer - WSAU
Generate Biomedicines prices IPO at $16 per share By Investing.com - Investing.com Australia
Generate Biomedicines Shares Plummet After $400 Million Market Debut - WSJ
U.S. IPO Weekly Recap: Asthma-Focused Generate Biomedicines Closes Out February IPO Market - Seeking Alpha
AI-Focused Generate Biomedicines Prices $400M IPO - Law360
Generate Biomedicines, AI-Driven Generative Biology Drug Developer, Files for Nasdaq Global Select Market IPO - TradingView
Generate Biomedicines Share Price Target and Forecast - Investing.com India
Generate Biomedicines’ IPO Brings In $400M for Pivotal Tests of Severe Asthma Drug - MedCity News
Generate Biomedicines stock opens below IPO price in Nasdaq debut By Investing.com - Investing.com South Africa
Generate Biomedicines stock opens below IPO price in Nasdaq debut - Investing.com Nigeria
Generate Biomedicines Shares Fall After Nasdaq Debut - marketscreener.com
Generate Biomedicines-Aktien fallen bei schwachem Nasdaq-Debüt des Arzneimittelentwicklers - TradingView
Generate Biomedicines shares fall 6% in weak Nasdaq debut for drug developer - TradingView
Flagship-backed Generate Biomedicines shares fall 6% in Nasdaq debut - marketscreener.com
Shares of Generate Biomedicines open at $15 in their Nasdaq debut vs $16 IPO price - marketscreener.com
Generate Biomedicines, Inc. share price - Capital.com
AI-driven drug developer nets $400M IPO, matching 2020 record - The Business Journals
Generate’s $400m IPO Adds To Biotech Bounceback - Citeline News & Insights
Rx Rundown: Gilead Sciences, Viatris, Generate Biomedicines and more - Medical Marketing and Media
Trade Generate Biomedicines, Inc.GENB CFD - Capital.com
Generate:Biomedicines Rings the Nasdaq Stock Market Opening Bell - Nasdaq
Generate:Biomedicines Rings the Opening Bell - Nasdaq
Generate Biomedicines secures $400m IPO in flurry of February listings - Yahoo Finance
Generate Biomedicines, Inc. Announces Pricing of Initial Public Offering - The Malaysian Reserve
Generate Biomedicines Announces IPO Terms for $400 Million Raise - Intellectia AI
GENB Stock Price, News & Analysis - Stock Titan
Drug developer Generate Biomedicines raises $400 million in US IPO - marketscreener.com
Generate caps a strong month for biotech IPOs with $400M offering - BioPharma Dive
AI biotech Generate Biomedicines raises $400M in IPO - Axios
Generate Biomedicines prices IPO at $16 per share - Investing.com
Lo sviluppatore di farmaci Generate Biomedicines raccoglie 400 milioni di dollari nell'IPO statunitense - TradingView
Flagship-Backed Generate Biomedicines Raises $400 Million in IPO - Bloomberg
GENBGenerate Biomedicines Latest Stock News & Market Updates - Stock Titan
Flagship-backed Generate Bio seeks $425 million in US IPO - MSN
Generate Biomedicines (GENB) Stock Forecast & Price Target - Investing.com
Generate Biomedicines IPO Closing Market Cap Trading Odds & Predictions - Polymarket
Generate Biomedicines Inc Consensus Estimates (GENB) - Investing.com South Africa
Operating expenses (excl. COGS) of Generate Biomedicines, Inc. – NASDAQ:GENB - TradingView
AI pharmaceutical company Generate Biomedicines (GENB.US) sets IPO price at $16 per share, to be listed on Nasdaq tonight - Bitget
Preview: Generate Biomedicines, Inc Set To IPO Tomorrow - Benzinga
Debt to equity ratio of Generate Biomedicines, Inc. – NASDAQ:GENB - TradingView
Operating cash flow per share of Generate Biomedicines, Inc. – NASDAQ:GENB - TradingView
CapEx per share of Generate Biomedicines, Inc. – NASDAQ:GENB - TradingView
EBIT per share of Generate Biomedicines, Inc. – NASDAQ:GENB - TradingView
3.96%
大文字化:
|
ボリューム (24 時間):